Insulin Manufacturing and Distribution Capabilities Currently Stable During COVID-19 Pandemic
March 24, 2020

At this time, the leading pharmaceutical manufacturers are reporting that COVID-19 is NOT having an impact on their manufacturing and distribution capabilities for insulin and other related supplies.

Additionally, most local business restrictions and closures do not include pharmacies and grocery stores (many of which also contain pharmacies).

People with diabetes are also expressing concerns about job loss and their ability to afford medication and supplies. Please use and share with your patients the following link to AACE’s online medication affordability resource, which provides a directory of most endocrine manufacturers’ patient-affordability programs and contact information: